Pulmonx (LUNG) revenue and earnings history
Pulmonx reported revenue of $90.5M for fiscal 2025 (year ended Dec 31, 2025), +8.0% on the year before, and net income of −$54M.
Over 7 years, from fiscal 2018 to fiscal 2025, revenue grew at a compound rate of +24.1% a year.
Revenue and net income, 8 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $90.5M+8.0% | −$53.7M | −$54M | −$32.4M | $452K | −$32.8M | $21.2M | — | — | $69.8M | $37.1M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Pulmonx (LUNG) on OQRO.
Common questions
What was Pulmonx's revenue in fiscal 2025?
$90.5M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 10, 2026. That is +8.0% on fiscal 2024 ($83.8M).
How fast has Pulmonx's revenue grown?
From $20M in fiscal 2018 to $90.5M in fiscal 2025: a compound annual growth rate of +24.1% over 7 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Pulmonx been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Pulmonx tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
